Cargando…
Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma
OBJECTIVES: The signet‐ring cell carcinoma (SRCC) of the stomach is highly invasive. Patients with stage III gastric SRCC usually experience tumor recurrence within 2 years after radical surgery. Unfortunately, there is no effective treatment to postpone recurrence following adjuvant chemotherapy. O...
Autores principales: | Ding, Naiqing, Liu, Qin, Du, Juan, Shao, Jie, Yang, Yang, Yang, Ju, Chen, Fangjun, Yu, Lixia, Liu, Baorui, Wei, Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494288/ https://www.ncbi.nlm.nih.gov/pubmed/37700856 http://dx.doi.org/10.1002/cti2.1467 |
Ejemplares similares
-
TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma
por: Yue, Guofeng, et al.
Publicado: (2014) -
Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report
por: Liu, Chenxi, et al.
Publicado: (2021) -
Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study
por: Shi, Tao, et al.
Publicado: (2019) -
The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy
por: Jin, Shenying, et al.
Publicado: (2017) -
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
por: Liu, Qin, et al.
Publicado: (2022)